Hsbc Holdings PLC Sells 6,138 Shares of DaVita Inc. $DVA

Hsbc Holdings PLC lowered its holdings in DaVita Inc. (NYSE:DVA) by 4.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 144,780 shares of the company’s stock after selling 6,138 shares during the period. Hsbc Holdings PLC owned approximately 0.20% of DaVita worth $20,618,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Capital Fund Management S.A. boosted its stake in shares of DaVita by 200.4% in the second quarter. Capital Fund Management S.A. now owns 45,894 shares of the company’s stock valued at $6,538,000 after buying an additional 30,615 shares during the period. Korea Investment CORP raised its holdings in DaVita by 690.4% in the 2nd quarter. Korea Investment CORP now owns 35,719 shares of the company’s stock valued at $5,088,000 after acquiring an additional 31,200 shares in the last quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund bought a new stake in shares of DaVita during the 2nd quarter valued at $242,000. Te Ahumairangi Investment Management Ltd grew its holdings in shares of DaVita by 39.1% during the 2nd quarter. Te Ahumairangi Investment Management Ltd now owns 58,861 shares of the company’s stock worth $8,385,000 after purchasing an additional 16,543 shares in the last quarter. Finally, Employees Retirement System of Texas bought a new position in shares of DaVita in the second quarter worth $49,000. 90.12% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Truist Financial set a $140.00 price objective on shares of DaVita in a research note on Tuesday, October 14th. TD Cowen reduced their price target on shares of DaVita from $154.00 to $133.00 and set a “hold” rating on the stock in a research report on Monday, November 3rd. Zacks Research raised shares of DaVita from a “strong sell” rating to a “hold” rating in a research note on Friday, November 28th. Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a research note on Monday. Finally, Bank of America reduced their target price on DaVita from $145.00 to $140.00 and set an “underperform” rating on the stock in a report on Wednesday, September 10th. Six investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $148.00.

DaVita Price Performance

Shares of DaVita stock opened at $119.08 on Wednesday. The company’s 50 day moving average price is $124.51 and its two-hundred day moving average price is $133.29. The firm has a market capitalization of $8.41 billion, a P/E ratio of 12.26, a P/E/G ratio of 0.90 and a beta of 1.00. DaVita Inc. has a fifty-two week low of $113.97 and a fifty-two week high of $179.60.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.17 by ($0.66). DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.The company had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.43 billion. During the same quarter last year, the company posted $2.59 earnings per share. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. On average, analysts expect that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.